 Kyle Rove
Concepts (301)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urologic Surgical Procedures | 12 | 2025 | 115 | 4.180 |
Why?
| | Prostatic Neoplasms | 17 | 2014 | 974 | 2.850 |
Why?
| | Urinary Bladder | 5 | 2025 | 194 | 1.960 |
Why?
| | Androgen Antagonists | 5 | 2014 | 91 | 1.810 |
Why?
| | Abdominal Neoplasms | 2 | 2025 | 47 | 1.750 |
Why?
| | Urology | 5 | 2024 | 64 | 1.660 |
Why?
| | Perioperative Care | 3 | 2024 | 231 | 1.630 |
Why?
| | Analgesics, Opioid | 8 | 2024 | 1143 | 1.540 |
Why?
| | Urodynamics | 5 | 2025 | 47 | 1.490 |
Why?
| | Postoperative Complications | 10 | 2025 | 2919 | 1.480 |
Why?
| | Urinary Bladder, Neurogenic | 3 | 2024 | 44 | 1.440 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 338 | 1.270 |
Why?
| | Length of Stay | 9 | 2025 | 1337 | 1.220 |
Why?
| | Spinal Dysraphism | 4 | 2025 | 114 | 1.020 |
Why?
| | Child | 37 | 2026 | 22633 | 1.000 |
Why?
| | Testosterone | 5 | 2015 | 419 | 0.990 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2025 | 28 | 0.880 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 255 | 0.870 |
Why?
| | Ileum | 1 | 2025 | 111 | 0.870 |
Why?
| | Testicular Neoplasms | 2 | 2016 | 113 | 0.860 |
Why?
| | Pediatrics | 4 | 2026 | 1114 | 0.850 |
Why?
| | Metabolic Diseases | 1 | 2025 | 114 | 0.840 |
Why?
| | Neuroblastoma | 1 | 2025 | 174 | 0.810 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1356 | 0.810 |
Why?
| | Kidney Calculi | 4 | 2025 | 45 | 0.810 |
Why?
| | Specialties, Surgical | 1 | 2025 | 82 | 0.810 |
Why?
| | Neoplasms, Hormone-Dependent | 2 | 2014 | 41 | 0.800 |
Why?
| | Physicians, Women | 1 | 2025 | 88 | 0.800 |
Why?
| | Surgeons | 2 | 2025 | 339 | 0.760 |
Why?
| | Urinary Bladder Diseases | 1 | 2022 | 18 | 0.750 |
Why?
| | Child, Preschool | 17 | 2025 | 11787 | 0.750 |
Why?
| | Drug Prescriptions | 1 | 2024 | 284 | 0.730 |
Why?
| | Propensity Score | 1 | 2024 | 367 | 0.730 |
Why?
| | Delphi Technique | 1 | 2024 | 329 | 0.730 |
Why?
| | Ureter | 1 | 2022 | 36 | 0.730 |
Why?
| | Lower Urinary Tract Symptoms | 2 | 2025 | 59 | 0.730 |
Why?
| | Prospective Studies | 15 | 2025 | 7990 | 0.720 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2014 | 212 | 0.710 |
Why?
| | Surgical Wound Infection | 1 | 2025 | 316 | 0.700 |
Why?
| | Urologic Diseases | 2 | 2018 | 40 | 0.660 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2020 | 25 | 0.660 |
Why?
| | Male | 45 | 2025 | 72315 | 0.650 |
Why?
| | Humans | 68 | 2026 | 144759 | 0.640 |
Why?
| | Analgesia | 1 | 2020 | 105 | 0.610 |
Why?
| | Hyperoxaluria, Primary | 3 | 2023 | 14 | 0.580 |
Why?
| | Wolfram Syndrome | 1 | 2018 | 5 | 0.560 |
Why?
| | Pons | 1 | 2018 | 33 | 0.550 |
Why?
| | Bone Neoplasms | 2 | 2011 | 253 | 0.550 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 653 | 0.540 |
Why?
| | Urination | 1 | 2018 | 48 | 0.540 |
Why?
| | Prostate-Specific Antigen | 4 | 2014 | 161 | 0.530 |
Why?
| | Adolescent | 20 | 2025 | 22428 | 0.530 |
Why?
| | Electronic Health Records | 2 | 2025 | 1173 | 0.520 |
Why?
| | Ureteroscopy | 3 | 2025 | 16 | 0.510 |
Why?
| | Recovery of Function | 2 | 2018 | 707 | 0.500 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.490 |
Why?
| | Cystoscopy | 1 | 2016 | 21 | 0.490 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 732 | 0.480 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 865 | 0.480 |
Why?
| | Bariatric Surgery | 1 | 2020 | 242 | 0.480 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.470 |
Why?
| | Cause of Death | 2 | 2023 | 471 | 0.450 |
Why?
| | Retrospective Studies | 16 | 2025 | 17066 | 0.420 |
Why?
| | Ureteral Calculi | 2 | 2025 | 16 | 0.420 |
Why?
| | Prostate | 2 | 2012 | 158 | 0.420 |
Why?
| | Lithotripsy | 2 | 2025 | 49 | 0.410 |
Why?
| | Orchiectomy | 4 | 2025 | 74 | 0.390 |
Why?
| | Patient Care Team | 2 | 2018 | 689 | 0.380 |
Why?
| | Female | 23 | 2025 | 78271 | 0.380 |
Why?
| | Radiotherapy | 3 | 2025 | 206 | 0.370 |
Why?
| | Pediatric Obesity | 1 | 2020 | 637 | 0.370 |
Why?
| | Incidence | 4 | 2024 | 2879 | 0.370 |
Why?
| | Tonsillectomy | 2 | 2024 | 105 | 0.350 |
Why?
| | Prognosis | 5 | 2025 | 4282 | 0.350 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2013 | 194 | 0.350 |
Why?
| | Treatment Outcome | 10 | 2025 | 11679 | 0.350 |
Why?
| | Azasteroids | 1 | 2011 | 5 | 0.340 |
Why?
| | 5-alpha Reductase Inhibitors | 1 | 2011 | 16 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2017 | 851 | 0.340 |
Why?
| | Anticarcinogenic Agents | 1 | 2011 | 61 | 0.320 |
Why?
| | Disease Progression | 4 | 2015 | 2847 | 0.320 |
Why?
| | Kidney Neoplasms | 3 | 2019 | 412 | 0.320 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2024 | 300 | 0.300 |
Why?
| | Young Adult | 9 | 2025 | 14105 | 0.300 |
Why?
| | Risk Assessment | 4 | 2024 | 3671 | 0.290 |
Why?
| | Registries | 1 | 2018 | 2385 | 0.290 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5408 | 0.280 |
Why?
| | Wilms Tumor | 2 | 2019 | 85 | 0.270 |
Why?
| | Neoplasm Staging | 4 | 2016 | 1462 | 0.270 |
Why?
| | Early Detection of Cancer | 2 | 2011 | 463 | 0.260 |
Why?
| | Adenoidectomy | 2 | 2024 | 81 | 0.240 |
Why?
| | Infant | 5 | 2025 | 10034 | 0.240 |
Why?
| | Sex Factors | 2 | 2025 | 2112 | 0.230 |
Why?
| | Antineoplastic Agents | 3 | 2012 | 2194 | 0.230 |
Why?
| | Pelvic Neoplasms | 1 | 2025 | 24 | 0.230 |
Why?
| | Nephrolithotomy, Percutaneous | 1 | 2025 | 5 | 0.230 |
Why?
| | Spermatic Cord Torsion | 1 | 2025 | 7 | 0.230 |
Why?
| | Urinary Tract | 1 | 2025 | 48 | 0.220 |
Why?
| | Case-Control Studies | 3 | 2023 | 3604 | 0.220 |
Why?
| | Fractures, Bone | 1 | 2009 | 414 | 0.210 |
Why?
| | Fecal Incontinence | 1 | 2025 | 91 | 0.210 |
Why?
| | Nephrocalcinosis | 1 | 2023 | 13 | 0.200 |
Why?
| | Nephrolithiasis | 1 | 2023 | 9 | 0.200 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 688 | 0.200 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 405 | 0.190 |
Why?
| | Risk Factors | 4 | 2025 | 10779 | 0.180 |
Why?
| | Meningomyelocele | 1 | 2023 | 61 | 0.180 |
Why?
| | Analgesia, Epidural | 1 | 2022 | 38 | 0.180 |
Why?
| | Pilot Projects | 2 | 2025 | 1886 | 0.180 |
Why?
| | Survival Analysis | 2 | 2016 | 1382 | 0.180 |
Why?
| | Hydrocephalus | 1 | 2023 | 111 | 0.180 |
Why?
| | Spinal Cord Injuries | 1 | 2025 | 240 | 0.170 |
Why?
| | Stents | 2 | 2023 | 556 | 0.170 |
Why?
| | Device Removal | 1 | 2022 | 143 | 0.170 |
Why?
| | Cohort Studies | 2 | 2024 | 5960 | 0.160 |
Why?
| | RANK Ligand | 2 | 2010 | 26 | 0.160 |
Why?
| | Diphosphonates | 2 | 2011 | 68 | 0.160 |
Why?
| | Anastomosis, Surgical | 1 | 2020 | 157 | 0.160 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6048 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 1266 | 0.150 |
Why?
| | Age Factors | 2 | 2018 | 3333 | 0.150 |
Why?
| | Sex-Determining Region Y Protein | 1 | 2019 | 7 | 0.150 |
Why?
| | WT1 Proteins | 1 | 2019 | 12 | 0.150 |
Why?
| | Emotions | 1 | 2024 | 578 | 0.140 |
Why?
| | Nephrotic Syndrome | 1 | 2019 | 44 | 0.140 |
Why?
| | Disorders of Sex Development | 1 | 2019 | 40 | 0.140 |
Why?
| | Urethral Neoplasms | 1 | 2018 | 2 | 0.140 |
Why?
| | Hypertension, Renal | 1 | 2018 | 15 | 0.140 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2018 | 6 | 0.140 |
Why?
| | Urethral Obstruction | 1 | 2018 | 8 | 0.140 |
Why?
| | Polyps | 1 | 2018 | 14 | 0.140 |
Why?
| | Renal Artery Obstruction | 1 | 2018 | 29 | 0.140 |
Why?
| | Caregivers | 2 | 2024 | 1049 | 0.140 |
Why?
| | Urethra | 1 | 2018 | 57 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3863 | 0.130 |
Why?
| | Prenatal Diagnosis | 1 | 2019 | 195 | 0.130 |
Why?
| | Intestines | 1 | 2020 | 358 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1560 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 598 | 0.130 |
Why?
| | Men's Health | 1 | 2017 | 6 | 0.130 |
Why?
| | Organ Size | 1 | 2018 | 463 | 0.130 |
Why?
| | Review Literature as Topic | 1 | 2017 | 53 | 0.130 |
Why?
| | Decision Making | 1 | 2024 | 975 | 0.130 |
Why?
| | Postoperative Period | 1 | 2018 | 354 | 0.120 |
Why?
| | Pain Management | 1 | 2020 | 405 | 0.120 |
Why?
| | Adult | 8 | 2024 | 40449 | 0.120 |
Why?
| | Quality Improvement | 1 | 2025 | 1289 | 0.120 |
Why?
| | Immunotherapy | 2 | 2011 | 653 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 189 | 0.120 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.120 |
Why?
| | Mitotic Index | 1 | 2015 | 25 | 0.120 |
Why?
| | Databases, Factual | 2 | 2022 | 1486 | 0.120 |
Why?
| | Intermittent Urethral Catheterization | 1 | 2015 | 4 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1053 | 0.110 |
Why?
| | Urination Disorders | 1 | 2015 | 15 | 0.110 |
Why?
| | Ultrasonography | 3 | 2019 | 770 | 0.110 |
Why?
| | Cloaca | 1 | 2015 | 52 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 508 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2016 | 769 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 845 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 965 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 488 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2011 | 1519 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 780 | 0.100 |
Why?
| | Self Report | 1 | 2018 | 872 | 0.100 |
Why?
| | Creatinine | 1 | 2015 | 506 | 0.100 |
Why?
| | Infant, Newborn | 4 | 2019 | 6429 | 0.090 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 17 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1539 | 0.090 |
Why?
| | Estrogens | 1 | 2015 | 380 | 0.090 |
Why?
| | Metalloporphyrins | 1 | 2012 | 66 | 0.090 |
Why?
| | Alpha Particles | 1 | 2011 | 1 | 0.090 |
Why?
| | Beta Particles | 1 | 2011 | 1 | 0.090 |
Why?
| | Drug Design | 1 | 2013 | 173 | 0.090 |
Why?
| | Quality of Life | 2 | 2018 | 3185 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 945 | 0.090 |
Why?
| | Clusterin | 1 | 2011 | 11 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3077 | 0.090 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2011 | 26 | 0.090 |
Why?
| | Receptors, Androgen | 1 | 2013 | 153 | 0.090 |
Why?
| | Mitomycin | 1 | 2011 | 32 | 0.090 |
Why?
| | Blood Chemical Analysis | 1 | 2012 | 109 | 0.090 |
Why?
| | Valproic Acid | 1 | 2011 | 47 | 0.090 |
Why?
| | Drug Costs | 1 | 2012 | 116 | 0.090 |
Why?
| | Kidney | 2 | 2019 | 1495 | 0.080 |
Why?
| | Dutasteride | 1 | 2011 | 5 | 0.080 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 68 | 0.080 |
Why?
| | United States | 4 | 2025 | 15966 | 0.080 |
Why?
| | Androstenols | 1 | 2010 | 4 | 0.080 |
Why?
| | Logistic Models | 1 | 2016 | 2117 | 0.080 |
Why?
| | Bone Density Conservation Agents | 1 | 2011 | 81 | 0.080 |
Why?
| | Tissue Extracts | 1 | 2010 | 19 | 0.080 |
Why?
| | Denosumab | 1 | 2010 | 10 | 0.080 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 40 | 0.080 |
Why?
| | Androstenes | 1 | 2010 | 17 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2011 | 42 | 0.080 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.080 |
Why?
| | Antigens, Neoplasm | 1 | 2012 | 271 | 0.080 |
Why?
| | Phenylthiohydantoin | 1 | 2010 | 44 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 583 | 0.080 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2011 | 139 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 589 | 0.080 |
Why?
| | Taxoids | 1 | 2010 | 116 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2947 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 710 | 0.080 |
Why?
| | Ultrasound, High-Intensity Focused, Transrectal | 1 | 2010 | 2 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 220 | 0.080 |
Why?
| | Hormone Antagonists | 1 | 2009 | 34 | 0.080 |
Why?
| | Benzamides | 1 | 2010 | 224 | 0.080 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 634 | 0.080 |
Why?
| | Nitriles | 1 | 2010 | 205 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2009 | 71 | 0.070 |
Why?
| | Mobility Limitation | 1 | 2009 | 66 | 0.070 |
Why?
| | Risk | 1 | 2011 | 911 | 0.070 |
Why?
| | Collagen Type I | 1 | 2009 | 147 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 549 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 291 | 0.070 |
Why?
| | Middle Aged | 6 | 2016 | 35875 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 4089 | 0.070 |
Why?
| | Aged | 4 | 2016 | 25913 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 881 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1313 | 0.060 |
Why?
| | Computer Simulation | 1 | 2011 | 1025 | 0.060 |
Why?
| | Software | 1 | 2011 | 690 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 969 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1720 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2026 | 282 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 985 | 0.050 |
Why?
| | Calcium Oxalate | 1 | 2023 | 7 | 0.050 |
Why?
| | Canada | 1 | 2025 | 428 | 0.050 |
Why?
| | Peptides | 1 | 2009 | 995 | 0.050 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2024 | 80 | 0.050 |
Why?
| | Polysomnography | 1 | 2024 | 235 | 0.050 |
Why?
| | Mass Screening | 1 | 2011 | 1347 | 0.050 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2023 | 44 | 0.050 |
Why?
| | Colostomy | 1 | 2022 | 28 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2115 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1953 | 0.040 |
Why?
| | Morphine | 1 | 2022 | 168 | 0.040 |
Why?
| | Animals | 3 | 2013 | 38058 | 0.040 |
Why?
| | Urologists | 1 | 2021 | 17 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1257 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5226 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2023 | 1095 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 156 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 488 | 0.040 |
Why?
| | Metanephrine | 1 | 2018 | 2 | 0.040 |
Why?
| | Cystography | 1 | 2018 | 2 | 0.040 |
Why?
| | Normetanephrine | 1 | 2018 | 3 | 0.040 |
Why?
| | Renin | 1 | 2018 | 34 | 0.030 |
Why?
| | Patient Readmission | 1 | 2024 | 758 | 0.030 |
Why?
| | Nephrectomy | 1 | 2019 | 158 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2019 | 173 | 0.030 |
Why?
| | Urinary Retention | 1 | 2018 | 25 | 0.030 |
Why?
| | Oxygen | 1 | 2023 | 995 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 421 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 406 | 0.030 |
Why?
| | Norepinephrine | 1 | 2018 | 196 | 0.030 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 197 | 0.030 |
Why?
| | Epithelium | 1 | 2018 | 314 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 704 | 0.030 |
Why?
| | Global Burden of Disease | 1 | 2017 | 23 | 0.030 |
Why?
| | Urologic Neoplasms | 1 | 2017 | 31 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 145 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2017 | 121 | 0.030 |
Why?
| | Infertility, Male | 1 | 2017 | 73 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 427 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 427 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 478 | 0.030 |
Why?
| | Urinary Diversion | 1 | 2015 | 13 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 316 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 157 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1489 | 0.030 |
Why?
| | Image-Guided Biopsy | 1 | 2012 | 41 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1694 | 0.020 |
Why?
| | Penis | 1 | 2012 | 32 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 38 | 0.020 |
Why?
| | Prostatectomy | 1 | 2012 | 93 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2012 | 87 | 0.020 |
Why?
| | Testis | 1 | 2012 | 163 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2012 | 307 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2015 | 760 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 357 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2310 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5868 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 103 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 919 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 797 | 0.020 |
Why?
| | DNA Damage | 1 | 2012 | 430 | 0.020 |
Why?
| | Workload | 1 | 2011 | 170 | 0.020 |
Why?
| | Safety | 1 | 2011 | 356 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1047 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2730 | 0.020 |
Why?
| | Skin | 1 | 2012 | 755 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2527 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7190 | 0.010 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1821 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5597 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3409 | 0.010 |
Why?
|
|
Rove's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|